US drug makers sue to block a federal regulation that would require them to display list prices for drugs in television advertisements; a proposal could lead to a broad settlement for opioid manufacturers that would issue a nationwide payout and prevent future lawsuits from local governments; Pfizer has agreed to buy Array BioPharma for $11.4 billion.
US drug manufacturers sued Friday to block a federal regulation from taking effect that would require them to list drug prices in television advertisements, The New York Times reported. HHS finalized the rule May 8, 2019; due to take effect in July, it represents one of the most high-profiile efforts by the Trump administration to lower prescription drug prices. Drug makers argued that list prices differ from patients' final costs, as list prices do not include rebates, discounts offered or patient assistance programs.
Pending approval by US District Judge Dan Aaron Polster, a proposal made Friday in an Ohio federal court by lawyers for hundreds of local governments could pave the way for a nationwide settlement with opioid manufacturers, according to The New York Times. The plan could expand the number of municipalities and counties eligible for compensation in federal litigation from 1650 to nearly 24,500. The proposal was suggested to provide a greater incentive for pharmaceutical companies tthat are defendants to comprehensively settle, as it would prevent future lawsuits from local governments.
In an effort to expand its presence in cancer research, Pfizer has agreed to buy Array BioPharma for $11.4 billion, paying $48 per share, The Washington Post reported. Last month, Array announced that its drugs Braftovi and Mektovi, along with another treatment, significantly improved overall survival in late-stage testing for some patients with colorectal cancer. Array planned to submit results to federal regulators later this year.
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More